留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

不容忽视的心肌炎——来自《2021年ESC急慢性心力衰竭诊断与治疗指南》的启示

邱露虹 刘颖娴 徐希奇

邱露虹, 刘颖娴, 徐希奇. 不容忽视的心肌炎——来自《2021年ESC急慢性心力衰竭诊断与治疗指南》的启示[J]. 协和医学杂志, 2022, 13(4): 530-534. doi: 10.12290/xhyxzz.2022-0077
引用本文: 邱露虹, 刘颖娴, 徐希奇. 不容忽视的心肌炎——来自《2021年ESC急慢性心力衰竭诊断与治疗指南》的启示[J]. 协和医学杂志, 2022, 13(4): 530-534. doi: 10.12290/xhyxzz.2022-0077
QIU Luhong, LIU Yingxian, XU Xiqi. Nonnegligible Myocarditis: Insights from 2021 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(4): 530-534. doi: 10.12290/xhyxzz.2022-0077
Citation: QIU Luhong, LIU Yingxian, XU Xiqi. Nonnegligible Myocarditis: Insights from 2021 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(4): 530-534. doi: 10.12290/xhyxzz.2022-0077

不容忽视的心肌炎——来自《2021年ESC急慢性心力衰竭诊断与治疗指南》的启示

doi: 10.12290/xhyxzz.2022-0077
基金项目: 

国家自然科学基金 82000470

详细信息
    通讯作者:

    徐希奇, E-mail:xuxiqi0928@163.com

  • 中图分类号: R542.2

Nonnegligible Myocarditis: Insights from 2021 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure

Funds: 

National Natural Science Foundation of China 82000470

More Information
  • 摘要: 2021年9月,Eur Heart J发布了《2021年ESC急慢性心力衰竭诊断与治疗指南》,该版指南对2016年版指南作出重要更新。其中,心肌炎作为心力衰竭的一种特定临床情况应给予重点关注。本文结合我国心肌炎临床诊疗实践,对新版指南中心肌炎部分进行全面解读,以加深临床医师对此类疾病的认识和理解。
    作者贡献:邱露虹负责查阅文献、撰写论文;徐希奇、刘颖娴负责审核及修订论文。
    利益冲突:所有作者均声明不存在利益冲突
  • 图  1  心力衰竭疑诊心肌炎患者的管理流程[1]

    ECG:心电图;CMR:心脏磁共振;CAG:冠状动脉造影;CAD:冠状动脉疾病;EMB:心内膜心肌活检;MCS:机械循环支持

  • [1] McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure[J]. Eur Heart J, 2021, 42: 3599-3726.
    [2] Dai H, Lotan D, Much AA, et al. Global, Regional, and National Burden of Myocarditis and Cardiomyopathy, 1990—2017[J]. Front Cardiovasc Med, 2021, 8: 610989. doi:  10.3389/fcvm.2021.610989
    [3] Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990—2013: a systematic analysis for the Global Burden of Disease Study 2013[J]. Lancet, 2015, 386: 743-800.
    [4] Heymans S, Eriksson U, Lehtonen J, et al. The Quest for New Approaches in Myocarditis and Inflammatory Cardiomyopathy[J]. J Am Coll Cardiol, 2016, 68: 2348-2364. doi:  10.1016/j.jacc.2016.09.937
    [5] Merken J, Hazebroek M, Van Paassen P, et al. Immunosuppressive Therapy Improves Both Short- and Long-Term Prognosis in Patients With Virus-Negative Nonfulminant Inflammatory Cardiomyopathy[J]. Circ Heart Fail, 2018, 11: e004228. doi:  10.1161/CIRCHEARTFAILURE.117.004228
    [6] Das M, Bristow MR, Chung MK. The Essential Vulner-ability of Human Cardiac Myocytes to SARS-CoV-2[J]. JACC Basic Transl Sci, 2021, 6: 346-349. doi:  10.1016/j.jacbts.2021.02.010
    [7] Grün S, Schumm J, Greulich S, et al. Long-term follow-up of biopsy-proven viral myocarditis: predictors of mortality and incomplete recovery[J]. J Am Coll Cardiol, 2012, 59: 1604-1615. doi:  10.1016/j.jacc.2012.01.007
    [8] Yeung C, Baranchuk A. Diagnosis and Treatment of Lyme Carditis: JACC Review Topic of the Week[J]. J Am Coll Cardiol, 2019, 74: 717-726. doi:  10.1016/j.jacc.2019.08.865
    [9] Moslehi JJ, Salem JE, Sosman JA, et al. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis[J]. Lancet, 2018, 391: 933.
    [10] Palaskas N, Lopez-Mattei J, Durand JB, et al. Immune Checkpoint Inhibitor Myocarditis: Pathophysiological Characteristics, Diagnosis, and Treatment[J]. J Am Heart Assoc, 2020, 9: e013757.
    [11] Caforio AL, Pankuweit S, Arbustini E, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases[J]. Eur Heart J, 2013, 34: 2636-2648, 2648a-2648d.
    [12] Staudt A, Schäper F, Stangl V, et al. Immunohistological changes in dilated cardiomyopathy induced by immunoadsorption therapy and subsequent immunoglobulin substitution[J]. Circulation, 2001, 103: 2681-2686.
    [13] Ammirati E, Cipriani M, Lilliu M, et al. Survival and Left Ventricular Function Changes in Fulminant Versus Nonfulmi-nant Acute Myocarditis[J]. Circulation, 2017, 136: 529-545.
    [14] Gannon MP, Schaub E, Grines CL, et al. State of the art: Evaluation and prognostication of myocarditis using cardiac MRI[J]. J Magn Reson Imaging, 2019, 49: e122-e131.
    [15] Felker GM, Thompson RE, Hare JM, et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy[J]. N Engl J Med, 2000, 342: 1077-1084.
  • 加载中
图(1)
计量
  • 文章访问数:  65
  • HTML全文浏览量:  7
  • PDF下载量:  24
  • 被引次数: 0
出版历程
  • 收稿日期:  2022-02-23
  • 录用日期:  2022-03-17
  • 网络出版日期:  2022-04-12
  • 刊出日期:  2022-07-30

目录

    /

    返回文章
    返回